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Helicobacter pylori reveals how the uptake of
human lipids enhances bacterial virulence†
Hau-Ming Jan,‡ab Yi-Chi Chen,‡ab Yu-Yin Shih,a Yu-Chen Huang,c Zhijay Tu,a
Arun B. Ingle,f Sheng-Wen Liu,a Ming-Shiang Wu,d Jacquelyn Gervay-Hague,e
Kwok-Kong Tony Mong,f Yet-Ran Chenc and Chun-Hung Lin*ab
Helicobacter pylori infects approximately half of the human population and is the main cause of various
gastric diseases. This pathogen is auxotrophic for cholesterol, which it converts upon uptake to various
cholesteryl a-glucoside derivatives, including cholesteryl 60-acyl and 60-phosphatidyl a-glucosides (CAGs
and CPGs). Owing to a lack of sensitive analytical methods, it is not known if CAGs and CPGs play
distinct physiological roles or how the acyl chain component affects function. Herein we established
a metabolite-labelling method for characterising these derivatives qualitatively and quantitatively with
a femtomolar detection limit. The development generated an MS/MS database of CGds, allowing for
profiling of all the cholesterol-derived metabolites. The subsequent analysis led to the unprecedented
information that these bacteria acquire phospholipids from the membrane of epithelial cells for CAG
biosynthesis. The resulting increase in longer or/and unsaturated CAG acyl chains helps to promote lipid
raft formation and thus delivery of the virulence factor CagA into the host cell, supporting the idea that
the host/pathogen interplay enhances bacterial virulence. These findings demonstrate an important
connection between the chain length of CAGs and the bacterial pathogenicity.Introduction
Infecting 50% of the world population, Helicobacter pylori
causes chronic gastritis, which is asymptomatic in the majority
of carriers but is considered a major risk factor for the devel-
opment of gastric and duodenal ulcers and gastric malignan-
cies, including mucosa-associated lymphoid tissue lymphoma
and gastric adenocarcinoma.1 This bacterium has an excep-
tional ability to persist and establish chronic infection, unlike
other Gram-negative bacterial pathogens, and representsSinica, No. 128 Academia Road Section 2,
hunhung@gate.sinica.edu.tw
artment of Chemistry, National Taiwan
Academia Sinica, Taipei, 11529, Taiwan
of Internal Medicine, National Taiwan
ifornia, Davis, CA, 95618, USA
l Chiao-Tung University, Hsin-Chu 300,
(ESI) available: General reagents and
supplementary schemes, synthetic
f selected compounds, supplementary
supplementary tables. See DOI:
is work.a highly successful pathogen because it is capable of evading,
subverting and manipulating the host's immune system.2,3 For
example, cytotoxin-associated gene A (CagA)4 is an H. pylori
virulence factor that enters host cells via type IV secretion
system (T4SS)-mediated translocation.5 CagA then undergoes
tyrosine phosphorylation by c-Src family kinases,6,7 and the
phosphorylated CagA then activates several cellular signalling
processes, including those leading to cancer development.8,9
Interestingly, the translocation process is not restricted to just
the transfer from H. pylori to the host. The pathogen also
receives molecules such as L-fucose10 and cholesterol3,11,12 from
the host for various purposes.
H. pylori assimilates cholesterol into its membrane by taking
up cholesterol from the medium or from epithelial cells of the
stomach.13 Upon uptake, the bacterial cells modify the choles-
terol by a-glucosylation. Specically, the glucosyltransferase
encoded by hp0421 catalyses the transfer of glucose to the 3b-
hydroxyl group of cholesterol, yielding cholesteryl a-D-gluco-
pyranoside (CG). An acyl or phosphatidyl group is then attached
to the O60 of glucose in CG to produce cholesteryl-60-O-acyl-a-D-
glucopyranoside (CAG) or cholesteryl-60-O-phosphatidyl-a-D-
glucopyranoside (CPG), respectively.14,15 These cholesteryl
glucoside derivatives (CGds) have been shown to be essential for
several physiological activities, such as antibiotic resistance,12
CagA translocation,16 the prevention of phagocytosis by
macrophages3 and the activation of invariant natural killer TThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinecells.17,18 CAG and CPG are further diversied by the addition of
different fatty acid chains to the acyl and phosphatidyl groups,
respectively. Owing to limitations in the purication and anal-
ysis, typically these CGds are examined collectively instead of
being separated and compared to determine whether the acyl or
phosphatidyl chain plays a role in an activity of interest.
Herein, we developed a specic metabolite-tagging method
to facilitate the purication and characterisation of H. pylori
CGds. Based on ultrahigh-performance liquid chromatography
mass spectrometry (UPLC-MS), this method not only allowed
the structural determination and quantitative characterisation
of all CGds, but also offered a great advantage in detection
sensitivity and the isolation of various CGds that are difficult to
obtain synthetically or by other means. Most importantly, the
resulting analysis demonstrated the incorporation of the host
phospholipids led to a signicant increase in CAGs containing
longer or/and unsaturated fatty acid chains. This change was
further found to promote the translocation and subsequent
phosphorylation of CagA through the enhanced formation of
lipid ras, demonstrating an interactive strategy to enhance
bacterial virulence.Results
Synthesis and evaluation of the tagged metabolites
Our metabolic labelling approach utilises azide-containing
cholesterol analogues in bacterial cell culture (Fig. 1). Aer the
cells were harvested, lipids were extracted and subjected to click
chemistry (1,3-dipolar cycloaddition) with a uorescently-tag-
ged alkyne. We rst examined the cholesterol analogues that are
comparable with cholesterol in terms of biosynthetic incorpo-
ration in vivo. We synthesised three azide-containing choles-
terol analogues, namely 17b-([30 0-azidopropoxy)-5-androsten-3b-
ol (compound 1), 17b-([60 0-azidohexanoxy)-5-androsten-3b-ol (2)
and 17b-([90 0-azidononanoxyl)-5-androsten-3b-ol (3), as shown
in the ESI Scheme 1.† These analogues all have the same four
fused rings as cholesterol, but differ in the azide-containing
side chain introduced at O17b. To evaluate if the three
analogues were suitable for incorporation into the biosynthetic
pathway, the cholesteryl a-glucosyltransferase gene hp0421 wasFig. 1 Schematic of the metabolic labelling of H. pylori CGds. 17b-
([30 0-Azidopropoxy)-5-androsten-3b-ol (1; an azide-containing
analogue of cholesterol) was added to H. pylori culture and incorpo-
rated into the biosynthetic pathway to produce various CGd
analogues. After harvest and Folch extraction, these analogues were
further reacted with a fluorescent alkyne ( ) via Cu(I)-catalysed 1,3-
dipolar cycloaddition to obtain the conjugated products, which were
then analysed by HPLC and MS.
This journal is © The Royal Society of Chemistry 2016cloned and the protein was then overexpressed and puried as
previously reported.15 Steady-state kinetics analysis (Table
S1†)19,20 demonstrated that the catalytic efficiency (kcat/Km)
values of compounds 1–3 are slightly smaller than that of
cholesterol, being in the range of 84–59% that of cholesterol. 1
appeared to be the best among the three and was thus selected
for the further investigations. Moreover, four other cholesterol
analogues (the structures of which are shown in Table S1†)
displayed much lower affinity for the enzyme, including ergos-
terol (13% that of cholesterol),15 stigmasterol (7%),15 22-NBD-
cholesterol (not detectable) and 25-NBD-cholesterol (not
detectable); with the last two compounds representing uores-
cent analogues widely used for imaging studies.21–23 The side
chain at C17 appeared to be critical to the enzymatic
glucosylation.
Compound 1 was evaluated by thin-layer chromatography
and phospholipid composition analyses24 to conrm that it was
equivalent to cholesterol in the biosynthesis of CGds (Fig. S1†).
The latter examined the levels of several phospholipids in
addition to CPG. The results indicated that 1 and cholesterol
yielded similar percentages of the major phospholipids in H.
pylori, including phosphatidylethanolamine (PE), cardiolipin
and phosphatidylglycerol.
We considered two factors when preparing suitable alkyne-
containing uorescent compounds for the click chemistry,
namely reactivity (potential yield) and stability. Two uo-
rophore-possessing alkynes were designed and synthesised,
such as 4-N-methylamino-1,8-napthalimidopropyne (MAN) and
4-N,N-dimethylamino-1,8-naphthalimidopropyne (DAN)25 (ESI
Scheme 2†). Both MAN and DAN, as well as several commer-
cially available uorescent dyes (Fig. S2B†), were examined by
Cu[I]-catalysed click chemistry. The reaction yield and stability
of MAN were higher than those of DAN and the other uores-
cent dyes (Fig. S2†).Structural determination and quantication of the CGds
For the metabolic labelling of CGds, H. pylori was treated with 1
and grown under microaerobic conditions at 37 C. Aer 4 days,
the bacterial cells were collected and subjected to Folch
extraction.26 The extracts were reacted withMAN in the presence
of tris(benzyltriazolylmethyl)amine, sodium ascorbate and
CuSO4 for 1 h. The resulting compounds were separated by
high-performance liquid chromatography and detected by
uorescence (HPLC-uorescence; C18-reversed-phase column;
lex ¼ 428 nm, lem ¼ 528 nm) (Fig. 2A). The CGds were also
identied by UPLC-MS in the product ion scanmode (Fig. 2B, S3
and Table S2†).27 HPLC-uorescence analysis revealed uo-
rophore-conjugated analogues of cholesterol and CG plus three
major groups of compounds, namely CAGs, CPGs and lyso-
CPGs (these uorophore-conjugated analogues of CAGs, CPGs
and lyso-CPGs derived from 1 are hereaer referred to as CAGs,
CPGs and lyso-CPGs, respectively, unless otherwise specied).
These compounds appeared in three groups in the HPLC
chromatogram due to differences in polarity. The structure of
each compound was identied by MS and conrmed by tandem
MS (MS/MS). The errors for the precursor m/z and for relativeChem. Sci., 2016, 7, 6208–6216 | 6209
Fig. 2 HPLC separation and identification of various fluorophore-
labelled CGds. (A) HPLC chromatogram of various labelled CGds,
including cholesterol, CG, CAGs, CPGs and lyso-CPGs. Compounds
were detected by fluorescence (lex ¼ 428, lem ¼ 528 nm). (B)
Molecular structure and MS analysis of CPG(14 : 0/19c : 0). The parent
ion was identified by ESI-MS and the fragmented ions by ESI-MS/MS.
The corresponding structures and molecular weights are indicated by
dashed arrows and numbers.
Fig. 3 Quantitative analysis of the labelled CGds. (A) Calibration curves
of CPG(14 : 0/19c : 0) based on HPLC-fluorescence (lex ¼ 428, lem ¼
528 nm) and UPLC-MS/MS operated in the product ion scan mode
with a specific fragment selected for extracted ion chromatography
quantification. The dynamic ranges of UPLC-MS/MS and HPLC-fluo-
rescence were 0.088–100 pmol and 2.8 pmol–100 nmol per 106
bacteria, respectively. (B) Levels of various CGds per 106 bacteria as
analysed by UPLC-MS/MS. (C) Enhanced ionization efficiency of flu-
orophore-labelled CGds in the mass spectrometry.H. pylori cells were
pretreated with cholesterol (white bar) or compound 1 (grey bar) for
two days. After harvest, the cholesterol-fed cells were extracted and
directly analysed by UPLC-MS, whereas the 1-pretreated cells were
extracted, labelled with MAN by click reaction and then analysed by
UPLC-MS. The normalised peak area was determined by the peak area
of CGds divided by the peak area of the internal standard (phosphoi-
nositol). N.D., not detected, denotes a ratio of signal to noise of below
three. Data shown were from three biological replicates. Error bars
represent the standard deviations. All the statistically significant
differences are indicated with asterisks; *P < 0.05, **P < 0.01, or ***P <
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View Article Onlineisotope abundance obtained by UPLC-MS were <5 ppm and 5%,
respectively (Table S2†). For instance, CPG(14 : 0/19c : 0) (see
Fig. 2B for the molecular structure) consists of two esteried
fatty acids : myristic acid (14 : 0) and another (19c : 0) that
contains a cyclopropane at C9 of the acyl chain.28,29 In the MS/
MS analysis of CPG(14 : 0/19c : 0), the predicted product ions
for the functional groups of the fatty acids, phosphate, glucose,
steroid, triazole and 4-N-methylamino-1,8-napthalimide (the
uorophore) were observed (Fig. 2B). The MS and correspond-
ing MS/MS data for the other CGds are provided in Fig. S3.†We
also performed 1H, 13C or/and 31P NMR analysis of CPG(14 : 0/
19c : 0) and CAG(14 : 0) (ESI† spectra data 1, 2 and 3) to conrm
that the phosphatidyl group is indeed attached to the O6 of
glucose and that C1 of the glucose forms an a-linkage with O3 of
the steroid.30 The phospholipases A1 and A2 (PLA1 and PLA2)
were applied in the UPLC-MS analysis31,32 to assign where the
two fatty acid chains of CPG(14 : 0/19c : 0) are attached to the
phosphatidyl glycerol. The fatty acids (14 : 0) and (19c : 0) were
found to be specically linked to the a1- and a2-positions,
respectively (Fig. S4A–C†). It was noted that acyl migration
occurred aer cleavage of CPG(14 : 0/19c : 0) at a1 using PLA1,
i.e. the majority of the remaining ester at the a2 position moved
to the a1 position via an intramolecular transfer (Fig. S4D–F†).33
Additionally, lyso-CPGs were found to exist as a mixture of
regioisomers, with the acyl chain attached to either the a1 or a2
position (Fig. S4G†). These were designated as 2-lyso-6210 | Chem. Sci., 2016, 7, 6208–6216CPG(19c : 0) or 1-lyso-CPG(19c : 0), respectively, indicating that
the ester at a2 or a1 is hydrolyzed.
HPLC-uorescence and UPLC-MS/MS were employed to
quantify the levels of CGds inH. pylori. The former was based on
the integration of signals in the LC chromatogram, whereas the
latter relied on the peak area of selected specic fragments for
the extracted ion chromatograms from using the Orbitrap
UPLC-MS system operated in the product ion scan mode. Table
S3† shows them/z of the designated target and fragmented ions
as well as the collision modes/energies. The chromatograms
(Fig. S5†) show the selected ion chromatograms of all the CGds
at m/z 366.16 or 620.36, which represent the m/z of the frag-
mented ions (daughter ions) shown in Table S3.† To quantify
the CGds and determine the sensitivity of detection, CPG(14 : 0/
19c : 0) was puried to >99% purity (determined by HPLC-
uorescence and UPLC-MS) and used to establish calibration
curves (Fig. 3A) in a linear range between 2.8 pmol and 100
nmol per 106 bacteria for HPLC-uorescence analysis, and
between 0.088 and 100 pmol for UPLC-MS/MS. The calibration
curves of CG, CAG(14 : 0), CPG(14 : 0/19c : 0) and lyso-0.001 based on student's t test.
This journal is © The Royal Society of Chemistry 2016
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View Article OnlineCPG(19c : 0) using UPLC-MS/MS and HPLC-uorescence are
also shown in Fig. S6.† In comparison with HPLC-uorescence,
UPLC-MS/MS was found to be more suitable for measuring the
CGds in very low abundance (<5 pmol per 106 bacteria), such as
CAG(18 : 0), CAG(18 : 2), CPG(14 : 0/16 : 0) and CPG(18 : 0/
18 : 0) (Fig. 3B). The detection sensitivity in UPLC-MS/MS for
the uorophore-conjugated derivatives (0.088 pmol) was
signicantly enhanced relative to the unconjugated analogues,
which is attributable to the dominant protonation of the
incorporated uorophore. In particular, whereas the native CG
and CAGs have no charge, the uorophore-conjugated
analogues had 100- and 10 000-fold enhanced intensities,
respectively (Fig. 3C).Fig. 4 Utilisation of human lipids for CAG and CPG biosynthesis in H.
pylori. Relative levels of (A) CAGs and (B) CPGs containing various acyl
chains. H. pylori (HP; standard type, 26695) was incubated with or
without human AGS cells for 6 h, and then CAGs and CPGs were
extracted from the cultures. “Others” includes the minor CPGs,
including CPG(18 : 0/19c : 0), CPG(19c : 0/19c : 0), CPG(18 : 0/18 : 0),
CPG(16 : 0/18 : 1) and CPG(18 : 1/18 : 1). (C) Relative levels of deute-
rium-labelled CAG and CPG in the culture of H. pylori. H. pylori was
treated with deuterium-labelled phosphatidylethanolamine (PE) or
phosphatidylcholine (PC) or palmitic acid (PMA) for 7 h and then
subjected to extensive washes to remove the unabsorbed compound.
Both PE and PC contained deuterium-labelled palmitic acid (16 : 0)
and unlabelled oleic acid (18 : 1). PMA contained deuterium-labelled
palmitic acid (16 : 0). The levels of deuterium-labelled CAG and CPG
(namely d-CAG and d-CPG, respectively), were quantified by UPLC-
MS/MS and calculated based on the abundance of spiked internal
standard (phosphoinositol). (D) Incorporation of deuterium-labelled
fatty acids from phospholipids into CAGs and CPGs. AGS cells were
treatedwith deuterium-labelled PE or PC for 1 h and then infectedwith
H. pylori (26695) for 6 h. PE and PC contained deuterium-labelled
palmitic acid (16 : 0) and unlabelled oleic acid (18 : 1). The levels of
deuterium-labelled CAGs and CPGs (d-CAG and d-CPG, respectively)
were determined by the area of the product ion signals in the UPLC-
MS spectra. Data shown are from three biological replicates. Error bars
represent the standard deviations. All statistically significant differ-
ences are indicated with asterisks; **P < 0.01 or ***P < 0.001 based on
Student's t test.Uptake of human phospholipids for CAG biosynthesis in H.
pylori
We next applied these labelling and analysis methods to
compare the lipid composition of CAGs and CPGs between H.
pylori cultured alone and co-cultures of H. pylori with AGS cells
(a human gastric cancer cell line; i.e. H. pylori-infected AGS
cells). Two major CAGs were observed in the bacterial cells
cultured alone (Fig. 4A), namely CAG(14 : 0) (93.7%) and
CAG(19c : 0) (4.0%), in agreement with the fact that these two
fatty acids are dominant in H. pylori.14 In contrast, the co-
cultured H. pylori generated signicant amounts of CAGs con-
taining longer or/and unsaturated acyl chains, such as
CAG(16 : 0), CAG(18 : 0), CAG(18 : 1), CAG(18 : 2) and
CAG(20 : 4) (Fig. 4A and S7A†). These lipid chains rarely exist in
H. pylori cultures, suggesting that they may have originated
from the human cells. Contrary to prediction, there was no
obvious difference in the lipid compositions or percentages of
CPGs between the bacterial culture and the co-culture (Fig. 4B
and S7B†).
We further examined the CAG and CPG compositions when
the AGS cells were co-cultured with different strains of H. pylori,
including the standard type (26695) and four clinical strains
isolated from patients with gastric cancer (GC1–GC4). UPLC-MS
analysis indicated that on average 83% of the total CAGs ob-
tained from the clinical isolates had incorporated human fatty
acid chains, including (16 : 0), (18 : 0), (18 : 1), (18 : 2) and
(20 : 4). In contrast, on average only 52% of CAGs from H. pylori
26 695 showed such incorporation (Fig. 5A). In particular, the
GC1–GC4 strains contained a higher content of CAG(18 : 1),
CAG(18 : 2) and CAG(20 : 4) (Fig. 5B), which have one or more
double bonds. There was no obvious difference in the lipid
composition of CPGs among any of these H. pylori strains
(Fig. 5C).
To search for a possible precursor in the biosynthesis, we
rst treated H. pylori cultures with deuterium-labelled PE,
phosphatidylcholine (PC) or palmitic acid (16 : 0) for 7 h to
examine the incorporation of deuterium-labelled acyl chains in
CAGs and CPGs. PE was found to be the major precursor in the
biosynthesis of CAGs and CPGs, although PC was also incor-
porated into CAGs to a small extent (Fig. 4C). Next, AGS cells
were pretreated with 1 for 24 h, and incubated with deuterium-
labelled PE or PC (the two major phospholipids in human cells)This journal is © The Royal Society of Chemistry 2016for 1 h. Because it is important to rule out the possibility of
adsorbing any lipids from culture dishes during the H. pylori
infection process, we extensively washed the phospholipid-
pretreated AGS cells with phosphate-buffered saline (PBS) and
then transferred the cells to new plates. The incorporation of
each phospholipid into AGS cells was monitored by UPLC-MS.
The cells were subsequently infected with H. pylori 26695 for 6 h
and then analysed by UPLC-MS to determine the proportion of
deuterium-labelled CAGs and CPGs. The analysis supported the
previous observation and demonstrated PE to be the primary
source for the acyl chains of CAGs and CPGs (Fig. 4D), and also
showed that the bacteria can obtain phospholipids from the
host cell for the synthesis of CAGs and CPGs. CPGs appeared to
have a much lower level of incorporation of the host phospho-
lipids than the CAGs (Fig. S7C and D†).Chem. Sci., 2016, 7, 6208–6216 | 6211
Fig. 5 Utilisation of human lipids for CAG biosynthesis in standard type
H. pylori and in clinical strains from patients with gastric cancer.
Standard type H. pylori (St; 26695) and clinical isolates (GC1–GC4)
were cultured with AGS cells, and the amounts of CAGs containing
different fatty acid chains were measured by UPLC-MS. (A) Ratio of
human-lipid-containing CAGs to total CAGs. (B) Relative levels of
CAGs containing different acyl chains. Human-lipid-containing CAGs
are composed of CAG(16 : 0), CAG(18 : 0), CAG(18 : 1), CAG(18 : 2)
and CAG(20 : 4). Total CAGs also include CAG(14 : 0) and
CAG(19c : 0), which are predominant in H. pylori. (C) Relative levels of
CPGs containing different fatty acid chains in H. pylori 26695 (St) and
the clinical strains isolated from patients with gastric cancer (GC1–
CG4). “Others” represents the total of minor CPGs, including
CPG(18 : 0/19c : 0), CPG(19c : 0/19c : 0), CPG(18 : 0/18 : 0),
CPG(16 : 0/18 : 1) and CPG(18 : 1/18 : 1). Data shown are from three
biological replicates. Error bars represent the standard deviations. All
statistically significant differences are indicated with asterisks; *P <
0.05, **P < 0.01, or ***P < 0.001 based on Student's t test.
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View Article OnlineEnhanced CagA translocation and lipid ra formation by
CAGs containing longer acyl chains
Because we were able to isolate individual CAGs and CPGs, we
further investigated the degree of inuence of each derivative
on the physiological activities. In the study of CagA trans-
location, we compared H. pylori 26695 to DCGT (a cholesterol
glucosyltransferase-decient strain (prepared as previously re-
ported16)) and to DCGT pretreated for 30 min with either
authentic CAG(14 : 0) (synthesised as previously reported34),
uorophore-labelled CAG(14 : 0) or uorophore-labelled
CPG(14 : 0/19c : 0) (Fig. 6A). CAG(14 : 0) and CPG(14 : 0/19c : 0)
are the most abundant CAG and CPG in H. pylori, respectively.
AGS cells were infected with the H. pylori strains for 1 h, and
then the cell extracts were immunoblotted with a CagA-specic
monoclonal antibody. There was no obvious difference between
pretreatment with labelled and authentic CAG, indicating that
uorophore-conjugated CGd analogues are comparable to the
corresponding native CGds and could be puried individually
for further investigation. Additionally, CAG was found, for the
rst time, to promote a higher degree of CagA translocation
than CPG (Fig. 6B). The result with authentic CAG was similar to
that of the positive control (H. pylori 26695), indicating that6212 | Chem. Sci., 2016, 7, 6208–6216CAGs are likely responsible for the observed activity among the
mixture of CGds.
We further investigated the effect of chain length on the
activity of CAGs. DCGT was pretreated for 30 min with three
CAGs of increasing chain length (CAG(10 : 0), CAG(14 : 0) and
CAG(18 : 0); Fig. 6B) and used to infect AGS cells. Analysis of
CagA translocation and the subsequent tyrosine phosphoryla-
tion35 demonstrated that the acyl chain length of CAGs indeed
plays a critical role in these activities (Fig. 6C). The degree of
CagA translocation and the corresponding phosphorylation
increased with the increasing chain length.
In addition, we examined whether the chain length of CAGs
correlates with lipid ra formation. Time-lapse uorescence
microscopy was performed to monitor the mobilisation of
ganglioside GM1-associated ras aer each CAG was added to
the AGS cells. GM1 in the AGS cells was labelled with Alexa-594-
cholera toxin prior to treatment with CAG(10 : 0), CAG(14 : 0) or
CAG(18 : 0). We found a time-dependent increase in uores-
cence intensity for all three CAGs, and further found that
CAG(18 : 0) induced the greatest accumulation of GM1 (Fig. 6D
and ESI movies†). Furthermore, when AGS cells were treated
with CAG(10 : 0), CAG(14 : 0) or CAG(18 : 0) for 30 min and then
labelled with GM1, the GM1 uorescence intensity increased
with increasing chain length (Fig. 6E and F). Taken together,
these results suggest that CAGs with incorporated human fatty
acids enhance the formation of lipid ras in the membrane,
which may lead to higher levels of CagA translocation and
subsequent phosphorylation.
Discussion
Click chemistry-based tagging methods have been prevalently
used in metabolite analysis. Our development appears to
provide several advantages. First, the introduced uorophore
MAN is readily protonated in solution, signicantly enhancing
the ionisation level in mass spectrometry (102 to 105-fold,
depending on the type of CGds). The combined mass spectro-
metric detection and enhanced ionisation of taggedmetabolites
made it possible to reach the detection limit at the femtomolar
level. Second, MAN was found to display a much higher stability
in comparison with several commercial uorescent dyes
(Fig. S2B†). The benecial features of high sensitivity and
stability support the idea that MAN should be useful for other
proling studies. Third, conventional analysis (e.g. 2D thin-layer
chromatography) is usually entangled with contamination from
phospholipids, explaining the reason why the relevant isolation
or purication becomes troublesome. In contrast, our devel-
opment makes the entire process more robust and it takes 2–3
weeks to obtain a single cholestyl glucosde derivative at the mg
level, including 7–10 days of culturing the bacteria. Aer
harvest, any of CGds can be made readily available with >95%
purity aer the bacterial cells are subjected to extraction with
organic solvents, followed by two steps of column chromatog-
raphy. Furthermore, the use of azide-containing compound 1
and the uorophore MAN is compatible for the purpose of
uorescent imaging to demonstrate how these labelled CGds
are translocated to and/or distributed in the host cell.This journal is © The Royal Society of Chemistry 2016
Fig. 6 Extent of CagA translocation and lipid raft formation under various conditions. (A) CagA translocation in AGS cells cultured with H. pylori
26695 (St), a cholesterol glucosyltransferase-deficient strain (DCGT), or DCGT pretreated for 30 min with fluorescently-labelled CAG(14 : 0)
(CAG-dye), fluorescently-labelled CPG(14 : 0/19c : 0) (CPG-dye) or authentic CAG(14 : 0) (au-CAG). Translocated CagA was detected by
immunoblotting before and 1 h after infection. (B) Structures of CAGs containing anO60 ester of decanoic acid (I), myristic acid (II) and stearic acid
(III). I carries the shortest fatty acid chain; while II and III carry themost abundant fatty acid chains inH. pylori and humans, respectively. (C) Effects
of CAGs with different acyl chains on CagA translocation and CagA tyrosine phosphorylation as detected by immunoblotting after the co-culture
of AGS cells with H. pylori strains for 4 h as described in (A). (D) Time-lapse images of AGS cells treated with CAGs (I, II or III). Lipid rafts (GM1) in
AGS cells were first labelled with Alexa Fluor 594-conjugated cholera toxin subunit b, followed by treatment with the indicated CAGs (10 : 0,
14 : 0 or 18 : 0) at 37 C. Time-lapse images were collected under a Zeiss LSM 510 confocal microscope at 0, 5, 10, 20 and 30 min. Scale bars, 5
mm. (E) Representative confocal immunofluorescence images for AGS cells that were first treated with CAGs (I, II or III) for 30 min prior to the
labelling of GM1. Scale bars, 10 mm. (F) Quantitation of the fluorescent intensities measured in (E). At least 40 GM1-positive AGS cells from each
treatment were scored for the quantitative analysis using ImageJ software. Statistical significance was evaluated using Student's t-test (*P < 0.05,
**P < 0.01 or ***P < 0.001). (G) The figure demonstrates how the uptake of human lipids enhances bacterial virulence. The resulting uptake
altered the bacterial CAG compositions (especially CAGs containing longer or/and unsaturated fatty acid chains), leading to a higher level of CagA
translocation and lipid raft formation.
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View Article OnlinePrevious ndings on the uptake of L-fucose from the host by
H. pylori indicate that this is a benecial strategy to acquire
additional carbon and energy, as well as to evade host immune
surveillance.10 Likewise, H. pylori has evolved to derive various
CGds from exogenous cholesterol, for which it is auxotrophic
(lacking biosynthetic machinery), but this is indispensable for
its pathogenesis and virulence.3,11,14 In this study, by using
a specic labelling method, we demonstrated that H. pylori also
acquires phospholipids from the host for CAG biosynthesis. The
acyl chain composition of H. pylori CAGs dramatically changed
in the presence of human host cells. For instance, CAG(14 : 0)
constituted 94% of the total CAGs when bacteria were cultured
alone, whereas when bacteria were cultured with human cells,
CAG(14 : 0) was reduced to 44% and was accompanied by CAGs
containing human fatty acid chains (52%; (16 : 0), (18 : 0),
(18 : 1), (18 : 2) and (20 : 4); Fig. 4A and S7A†). This alteration
led to a higher level of CagA translocation, indicating that
accessing human phospholipids enhances bacterial virulence
by altering the bacterial CAG compositions (Fig. 6G). Interest-
ingly, Hatakeyama et al. found that host phosphatidylserine is
aberrantly externalised from the inner to the outer leaet of the
host plasma membrane at the site of H. pylori attachment,
which facilitates the delivery, intracellular localisation and
pathophysiological activity of CagA.36 This nding suggestsThis journal is © The Royal Society of Chemistry 2016a mechanism for the release of host phospholipids during
bacterial infection.36
Cholesterol is an important component of cell membranes.
Particularly in lipid ras, this molecule serves as a glue to
maintain the close packing of lipids and proteins. H. pylori
CGds can be considered modied versions of cholesterol with
the additional attachment of glucose, acyl and/or phosphatidyl
groups. CAGs, CPGs and lyso-CPGs likely play different roles in
membranes. Wang et al. reported that CagA translocation is
mediated in a cholesterol-dependent manner, as the formation
of CGds from host cholesterol promotes the translocation of
CagA by affecting the membrane dynamics and enhancing lipid
ra formation.11,16 Our study identied CAGs, but not CPGs, as
being responsible for the enhanced translocation of CagA and
for the formation of lipid ras. An altered CAG composition
therefore has multifaceted effects. Lipid ras have been
demonstrated to serve as the obligate structure for the entry of
bacterial and viral pathogens.37,38
Our ndings further demonstrate that only CAGs with
longer acyl chains exert this effect to promote lipid ra
formation and thus CagA translocation. This result is consis-
tent with a number of previous reports. For instance, lipid
ras containing palmitoylated or stearoylated (C16/C18) GPI-
anchored variant surface glycoprotein display a higherChem. Sci., 2016, 7, 6208–6216 | 6213
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View Article Onlineresistance to Triton X-100 extraction than those containing
myristoylated (C14) GPI-anchored variant surface glycopro-
tein.39,40 Several ra-associated proteins are palmitoylated.41,42
When cytoplasmic proteins are subjected to lipidation, the
presence of at least one palmitate chain, rather than the
shorter myristoylate, is required for ra association.40,43 These
studies support the idea that acquired host CAG(16 : 0) and
CAG(18 : 0), rather than the plentiful bacterial CAG(14 : 0),
assist in the formation of lipid ras to enhance the subsequent
CagA translocation.
We also demonstrated that bacterial strains obtained from
patients with gastric cancer displayed a signicant increase in
CAGs carrying unsaturated acyl chains, i.e. CAG(18 : 1),
CAG(18 : 2) and CAG(20 : 4). Brewster and Safran demonstrated
that hybrid lipids (comprising one fully saturated and one
partially unsaturated chain) serve as a surface-active component
by occupying the interface between the lipid ra (facing the
saturated anchor) and the less-ordered environment (facing the
unsaturated chain).44 These reports suggest that the unsatu-
rated chains of CAG(18 : 1), CAG(18 : 2) and CAG(20 : 4) may
contribute to the ra structure by interacting with less-ordered
lipids.
Steryl glycosides (SGs) are known to prevalently exist in many
organisms and some of SGs are also acylated at the C60 position
of the sugar moiety, like CAGs in H. pylori. In general, there are
two possible routes regarding enzymatic acyl transfer: one
requires acyl-CoA as the donor, while the other needs a different
substrate for the same purpose. The acylation of several plant
steryl glucosides were found to be independent of acyl-CoA.
Instead, phosphoglycerolipids or/and galactolipids (fatty acids
attached to C1 and C2) were employed for the enzymatic
transfer of fatty acids.45 In AGS cells, PE and PC are the major
phospholipids. PE is also the major phospholipid in H. pylori.
To search for a possible precursor in the biosynthesis of CAG,
PE, PC and fatty acid (PMA) were individually added to the
bacterial culture to examine the incorporation of exogenous acyl
chains (i.e. deuterium-labelled acyl chains in CAG). As shown in
Fig. 4C, PE was found to be the major precursor in the biosyn-
thesis of CAG, while little or no PMA was incorporated into the
CAGs. This result supports there being a lipid-dependent acyl-
transferase involved in the biosynthesis of CAGs, and that PE is
a better substrate for this enzyme.
To explain the observed uptake of human phospholipids, it
appears to be essential to understand where the discussed
acyltransferase is located in H. pylori, since the incorporation of
deuterium-labelled acyl chain primarily occurred in CAGs but
not in CPGs. We propose that the CAG-related enzyme resides at
the bacterial outer membrane, making the direct access of
human phospholipids possible. As a matter of fact, several
studies have suggested that the biosynthetic location of CAGs is
indispensable for their release to the surface of host cells and
for the subsequent induction of the cytokines TNF-a and INF-
g.18 On the other hand, the unknown phosphatidyltransferase,
to convert CG to CPG, might be located at either the inner
membrane or at the cytoplasm, which would hamper the access
of the host phospholipids.6214 | Chem. Sci., 2016, 7, 6208–6216Conclusions
We established a metabolite-tagging method for the robust
detection of CGds at femtomolar sensitivity. The quantitative
analysis of CGds indicated that these bacteria utilise phos-
pholipids from human host cells to produce cholesteryl 60-acyl
a-glucosides (CAGs) containing longer/unsaturated fatty acid
chains. Our ndings demonstrate, for the rst time to the best
of our knowledge, that phospholipid hijack is the key to
augment the pathogenicity. Because the incorporated uo-
rophore displayed great inherent stability and a high ionisation
degree in mass spectrometry, the development should be
applicable to other metabolic proling.
Experimental
Metabolic labelling of CGds
H. pylori cells were seeded on Brucella agar plates containing 1
(50 mM) for 2–4 days. Bacterial lipids were extracted by the Folch
method,26 redissolved in chloroform/methanol/water (5 : 4 : 1,
v/v/v) and subjected to a click reaction with 0.25 mMMAN in the
presence of 1.25mM TBTA, 12.5 mM sodium ascorbate and 0.25
mM CuSO4 at room temperature for 1 h. The solvent was
removed in vacuo, and the dried residue was redissolved in
chloroform/methanol/water (5 : 4 : 1, v/v/v) and analysed by
HPLC and UPLC-MS.
HPLC analysis
For the experiments described in Fig. 2A, an analytical Inspire
C18 column (5 mm, 4.6  250 mm) was used at a ow rate of 0.4
mL min1. To obtain uorophore-labelled CAG(14 : 0) and
CPG(14 : 0/19c : 0) for NMR characterisation, a preparative
Inspire C18 column (5 mm, 21.5  250 mm) was used at a ow
rate of 6.5 mL min1. For quantication of the CGds using
HPLC-uorescence, an analytical Inspire C18 column (5 mm, 4.6
 250 mm) was used at a ow rate of 0.4 mL min1. In all the
experiments, eluent A contained 30% acetonitrile and 70%
aqueous 20 mM ammonium acetate, while eluent B contained
90% isopropyl alcohol and 10% aqueous 20 mM ammonium
acetate.
UPLC-MS analysis
UPLC-MS analysis was performed on a linear ion trap-Orbitrap
mass spectrometer (Orbitrap Elite; Thermo Fisher Scientic)
coupled online with a UPLC system (ACQUITY UPLC; Waters).
The mass spectrometer was operated in the positive electro-
spray ion mode set to one full FT-MS scan (m/z 200–1600; 15 000
resolution) and switched to different FT-MS product ion scans
(15 000 resolution) for the different CGd precursors. The CGds
were separated on a CSH C18 column (1.7 mm, 100  2.1 mm;
Waters, USA) using gradients of LC buffer A (10 mM ammonium
acetate in 40 : 60 [v/v] acetonitrile/water) and LC buffer B (10
mM ammonium acetate in 90 : 10 [v/v] isopropyl alcohol/
acetonitrile) at a ow rate of 0.4 mL min1. To normalise the
variations in sample preparation and UPLC-MS analysis, phos-
phatidylinositol containing deuterium-labelled palmitic acidThis journal is © The Royal Society of Chemistry 2016
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View Article Online(16 : 0) and unlabelled oleic acid (18 : 1) was used as the
internal standard and added to the bacterial lysate (106 bacteria,
determined by optical density at 600 nm). To determine the
ionisation efficiency of the CGds with or without MAN labelling,
the normalised peak area was dened as the peak area of CGds
divided by the peak area of the internal standard. To quantify
the MAN-labelled CGds from the bacterial lysates, the peak area
of selected specic fragments for the extracted ion chromato-
grams was used. To establish the calibration curves of CGds, we
added puried MAN-labelled cholesterol, CG, CAG(14 : 0),
CPG(14 : 0/19c : 0) and Lyso-CPG(19c : 0) to the lysate from 106
bacteria along with the click chemistry reactants (TBTA, sodium
ascorbate and CuSO4). The calibration curves for quantitation
were obtained by analysing the peak areas of the serially diluted
standard (0.088, 0.176, 0.35, 0.7, 1.4, 2.8, 5.6, 11.25, 22.5, 45 and
90 pmol per 106 bacteria) measured by UPLC-MS operated in the
product ion scan mode. The amount of CGds in the bacterial
lysate was determined by comparing the peak area in lysate to
the standard curves. The relative isotopic abundance error was
calculated as previously described.27Co-culture experiments
Co-culture experiments were performed as previously
described.16 In the experiments described in Fig. 4A, B and 5,
AGS cells (8.0  106) were seeded in a 10 cm tissue culture dish
and treated with 1 (6.2 mg mL1) in Dulbecco's Modied Eagle
Medium (DMEM) (Gibco, Invitrogen) at 37 C for 16 h. AGS cells
were infected with H. pylori (26695 or clinically isolated strains)
at an MOI of 200 : 1 for 6 h and subsequently collected by
centrifugation (6000  g) for 5 min. CGds-containing lipids
were isolated by Folch extraction and uorescently labelled by
click reaction for UPLC-MS analysis. With respect to the study
shown in Fig. 4D, AGS cells (8.0  106) were seeded in a 10 cm
tissue culture dish and treated with 1 (6.2 mg mL1) in DMEM at
37 C for 16 h. To label AGS cells with deuterium-labelled
phospholipid, the AGS cells were incubated with serum-free
medium (Ham's F12, Invitrogen) containing 0.1 mM 1-palmi-
toyl(d31)-2-oleoyl-sn-glycero-3-phosphoethanolamine (dPOPE;
16 : 0 d31 : (18 : 1)) or 0.1 mM 1-palmitoyl(d31)-2-oleoyl-sn-
glycero-3-phosphocholine (dPOPC; 16 : 0 d31 : (18 : 1)) (Avanti
Polar Lipids, USA) at 37 C for 1 h. It is important to wash the
cells with PBS ve times to remove unbound 1 and dPOPE or
dPOPC. Then the cells were transferred to a new plate for
another 12 h. To demonstrate that the bacterial uptake of
deuterium-labelled phospholipids was from the cells rather
than the phospholipids remaining on the culture dish, empty
culture dishes were rst treated with 1 for 16 h, treated with
POPE or dPOPC for another 1 h, washed with PBS ve times,
and then used to culture H. pylori without AGS cells for 6 h. No
deuterium-labelled CGds were produced by H. pylori under
these conditions. To perform the infection experiments,
unloaded or dPOPE/dPOPC-loaded AGS cells were infected with
H. pylori (26695) at an MOI of 200 : 1 for 6 h and subsequently
collected by centrifugation (6000  g) for 5 min. CGds-con-
taining lipids were isolated by Folch extraction and uo-
rescently labelled by click reaction for UPLC-MS analysis. ForThis journal is © The Royal Society of Chemistry 2016the CagA translocation experiments, AGS cells (8.0  105) were
seeded in DMEM (Gibco, Invitrogen) in a 6-well culture plate at
37 C for 16 h. To load H. pylori cells with CGds, H. pylori cells
(26695 or DCGT) were incubated with serum-free medium
(Ham's F12) containing 30 mM of MAN-labelled CAG(14 : 0),
MAN-labelled CPG(14 : 0/19c : 0) or unlabelled CAG standard at
37 C for 30 min. The bacterial cells were then washed with PBS
to remove unbound CPG or CAG and then used to infect AGS
cells at an MOI of 200 : 1 for 1 h.Immunoprecipitation and blotting
Aer the infection of AGS cells with H. pylori (MOI of 200 : 1),
the cells were washed three times with PBS and collected with
a cell scraper. To detect the internalised CagA to AGS cells,
saponin was used to lyse the AGS cells, but with care to keep the
bacteria intact.5,35 The AGS cells were gently lysed with PBS
containing 0.1% saponin, protease inhibitor cocktail (Calbio-
chem, USA) and phosphatase inhibitor cocktail (Calbiochem,
USA) for 10 min at room temperature. The cell debris and intact
bacteria were separated from the soluble fraction by centrifu-
gation (6000  g for 5 min), and the solute was ltered with
a 0.22 mm-pore lter to obtain human cell proteins and the
internalised CagA. The saponin lysis procedure was also per-
formed on standard type H. pylori (26695) alone. Subsequent
immunoprecipitation and blotting of CagA indicated that no
CagA was detected, supporting the idea that this procedure did
not release cytoplasmic proteins from H. pylori (data not
shown). The ltrate (100 mg) was immunoprecipitated using 10
mg rabbit anti-CagA polyclonal antibody (Austral Biologicals,
USA) and 30 ml Protein A Plus Agarose (Thermo scientic, USA)
at 4 C overnight. The obtained precipitates were washed three
times with immunoprecipitation buffer (25 mM Tris–HCl (pH
7.4), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100) and once
with TBS buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM
CaCl2), then boiled in PAGE sample buffer (62.5 mM Tris–HCl,
pH 6.8, 2% SDS, 10% (v/v) glycerol, 0.05% brilliant blue R) at 95
C for 10 min, resolved by 6% SDS-PAGE and then transferred
onto polyvinylidene diuoride membranes (Millipore, USA).
The membranes were blocked with 5% (w/v) skimmed milk in
TBS buffer containing 0.01% Tween 20 at room temperature for
1 h and incubated overnight with mouse monoclonal anti-CagA
(Austral Biologicals; 1 : 2000), mouse monoclonal anti-phos-
photyrosine (4G10, Millipore; 1 : 2000) or mouse monoclonal
anti-GAPDH (ab9482, Abcam, UK; 1 : 5000) at 4 C. The blots
were washed and incubated with HRP-conjugated secondary
antibodies (Santa Cruz Biotechnology, USA) at a 1 : 5000 dilu-
tion, and the proteins of interest were visualised using an
enhanced chemiluminescence assay (WBKLS0500, Millipore).
See the ESI† for additional information.Acknowledgements
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